Advanced Metastatic Colorectal Cancer - FUSILEV? Receives Unique, Product-Specific J-Code From The CMS, USA

Spectrum Pharmaceuticals, Inc., (NasdaqGM:SPPI) announced today that the Centers for Medicare and Medicaid Services (CMS), under the Medicare Part B benefit, has assigned a unique, product-specific billing code, or J-code, for FUSILEV? (levoleucovorin). FUSILEV? is the only commercially available formulation comprised only of the pharmacologically active isomer of leucovorin.

More: continued here

Filed under: Colorectal Cancer on November 21st, 2008